Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 8,274 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Risk Clear all

Conditions: Prejudice
Interventions: mortality salience; Procedure
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: Not listed
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Cardiovascular Risk Factors, Serious Mental Illness
Interventions: IDEAL intervention, Control; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Woodlawn, Maryland

Conditions: Prostate Cancer
Interventions: Casodex, Eulexin, LHRH agonist, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 1,579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2022
U.S. locations: 241
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more

Conditions: Substance Abuse, HIV Infections
Interventions: mirtazapine, placebo; Drug
Lead sponsor: San Francisco Department of Public Health; Government
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Balance Training, Breathing and Stretching Exercises; Other
Lead sponsor: Texas Woman's University; Other
Eligibility: 60 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Houston, Texas • Sugar Land, Texas • Webster, Texas

Conditions: Smoking Cessation, Smoking, Cigarette, Nicotine Dependence
Interventions: sirolimus, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions: Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation; Drug · Other · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 50 Years to 75 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 3
States / cities: Salt Lake City, Utah • Seattle, Washington

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: SPRX002, ARC-T Cells, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Duarte, California • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Leukemia, Acute Myeloid Leukemia, AML
Interventions: Selinexor, Daunorubicin, Cytarabine; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hypertension, Aging
Interventions: Exercise, ACE inhibitor + exercise, Thiazide diuretic + exercise, Angiotensin receptor blocker + exercise; Behavioral · Drug
Lead sponsor: University of Florida; Other
Eligibility: 65 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Moderated-high Risk of Postoperative Pulmonary Complication, Abdominal Surgery Expected More Than Two Hours
Interventions: Alveolar recruitment maneuver, Calculation of optimal PEEP, Postoperative CPAP; Procedure
Lead sponsor: Fundación para la Investigación del Hospital Clínico de Valencia; Other
Eligibility: 18 Years and older
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
Interventions: Abemaciclib, Tamoxifen, Anastrozole, Letrozole, Exemestane, LHRH Agonist; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 12
States / cities: Stamford, Connecticut • Brewer, Maine • Scarborough, Maine + 7 more

Conditions: Meningioma
Interventions: Lutathera; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: New York, New York • Cleveland, Ohio

Conditions: Glaucoma
Interventions: Efficacy-patient navigator to improve follow-up adherence, Office-Based Usual Care; Behavioral
Lead sponsor: Wills Eye; Other
Eligibility: 50 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Malignant Female Reproductive System Neoplasm, Gynecologic Cancer, Gynecologic Neoplasm
Interventions: Physical function assessment, Self-reported Assessments and Questionnaires, Surgery (Standard of Care, Non-Interventional); Other · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 2
States / cities: San Francisco, California • Boston, Massachusetts

Conditions: Suicidal and Self-injurious Behavior
Interventions: Safety Study Lethal Means Counseling; Behavioral
Lead sponsor: Northeastern University; Other
Eligibility: 10 Years to 17 Years
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Colorado Springs, Colorado • Fort Collins, Colorado • Loveland, Colorado + 2 more

Conditions: Drug Hypersensitivity
Interventions: No intervention; Other
Lead sponsor: Takeda; Industry
Eligibility: 2 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Bicuspid Aortic Valve
Interventions: Medtronic TAVR Systems; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 60 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 25
States / cities: Phoenix, Arizona • La Jolla, California • Thousand Oaks, California + 21 more

Conditions: Musculoskeletal Injury, Musculoskeletal Illness
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Post Operative Surgical Site Infection
Interventions: Vancomycin antibiotic powder; Drug
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1,036 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Burns
Interventions: Routine change of central venous catheters; Other
Lead sponsor: Shriners Hospitals for Children; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Interstitial Lung Diseases
Interventions: Nerandomilast, Placebo matching nerandomilast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 25 more

Conditions: Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
Interventions: Pembrolizumab, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, Biopsy, Questionnaire Administration; Biological · Drug · Procedure + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 429
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 340 more

Conditions: Caregiver Stress, Caregiver Health Related QOL, Caregiver Mental Health, Caregiver Health Status, Recruitment of Participants, Elder Mistreatment
Interventions: CSNAT-I; Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Galveston, Texas

Search by objective public record fields.

The Psychosocial Effect of Thoughts of Personal Mortality on Cardiac Risk Assessment by Medical Students

Intervention Trial to Decrease Cardiovascular Risk in Persons With Serious Mental Illness

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors

The Prescriptive Validity of a Novel Fall Risk Clinical Prediction Rule for People With COPD

Enhancing Self Regulation Among Smokers

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

ACE Inhibitors Combined With Exercise for Seniors - Pilot Study

Individualized Perioperative Open Lung Ventilatory Strategy

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma

Comparison Study of Glaucoma Eye Care Follow-Up Adherence in a High Risk Population

PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery

An ED-based RCT of Lethal Means Counseling for Parents of At-Risk Youth

A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood of Children, Teenagers and Adults

Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study

Reducing Musculoskeletal Stresses and Work-related Injuries Among Allied Health Professionals in Surgical Care

Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)

Central Venous Catheter Replacement Strategies in Patients With Acute Burn Injury

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Applying CSNAT in HBPC as an Approach to Elder Mistreatment Risk Reduction